RESULTS: In the NIS database, from the years 2016 to 2018, a total of 6233 and 2524 patients who underwent SMVr and TEER were selected, respectively. The mean ages of the patients were 65.68 years (SMVr) and 78.40 years (TEER) (p < 0.01). The mortality rate of patients who received SMVr was similar to that of patients who were treated with TEER (1.7% vs. 1.9%, p = 0.603). Patients who underwent SMVr more likely suffered from perioperative complications including cardiogenic shock (2.3% vs. 0.4%, p < 0.001), cardiac arrest (1.7% vs. 1.1%, p = 0.025), and cerebrovascular infarction (0.9% vs. 0.4%, p = 0.013). The average length of hospital stay was longer (8.59 vs. 4.13 days, p < 0.001) for SMVr compared to TEER; however, the average cost of treatment was higher ($218 728.25 vs. $215 071.74, p = 0.031) for TEER compared to SMVr. Multiple logistic regression analysis showed that SMVr was associated with worse adjusted cardiogenic shock (OR, 7.347 [95% CI, 3.574-15.105]; p < 0.01) and acute kidney injury (OR, 2.793 [95% CI, 2.356-3.311]; p < 0.01).
CONCLUSIONS: Patients who underwent TEER demonstrated a notable decrease in postoperative complications and a shorter hospitalization period when compared to those who underwent SMVr.
结果:在NIS数据库中,从2016年到2018年,共选择了6233名和2524名接受SMVr和TEER的患者,分别。患者的平均年龄为65.68岁(SMVr)和78.40岁(TEER)(p<0.01)。接受SMVr的患者的死亡率与接受TEER治疗的患者的死亡率相似(1.7%vs.1.9%,p=0.603)。接受SMVr的患者更有可能发生围手术期并发症,包括心源性休克(2.3%vs.0.4%,p<0.001),心脏骤停(1.7%vs.1.1%,p=0.025),和脑血管梗塞(0.9%vs.0.4%,p=0.013)。平均住院时间更长(8.59vs.4.13天,与TEER相比,SMVr的p<0.001);然而,平均治疗费用较高($218728.25vs.与SMVr相比,TEER为215071.74美元,p=0.031)。多因素logistic回归分析显示SMVr与更差的调整心源性休克(OR,7.347[95%CI,3.574-15.105];p<0.01)和急性肾损伤(OR,2.793[95%CI,2.356-3.311];p<0.01)。
结论:与接受SMVr的患者相比,接受TEER的患者术后并发症显著减少,住院时间更短。